Gut Inflammation & Genes: New Link to Disease Risk

Inflammatory bowel disease (IBD), a chronic condition affecting millions worldwide, may soon be approached with a more personalized treatment strategy thanks to groundbreaking research from the University of California, Riverside. Two new studies, published concurrently in Gut Microbes, pinpoint a critical gene, PTPN2, and its role in maintaining gut health and protecting against harmful bacteria – offering a potential pathway to targeted therapies for those genetically predisposed to IBD.

For years, researchers have understood that IBD – encompassing Crohn’s disease and ulcerative colitis – involves a complex interplay of genetic factors, immune responses, and the gut microbiome. However, identifying specific genetic vulnerabilities has remained a significant challenge. This research directly addresses that gap, focusing on PTPN2, a gene known to regulate immune cell function. The studies reveal that when PTPN2 doesn’t function optimally, the gut’s natural defenses are compromised, allowing pathogenic bacteria, particularly adherent-invasive E. coli (AIEC), to flourish.

AIEC is frequently found in higher concentrations in IBD patients. Unlike benign E. coli strains, AIEC can adhere to and invade the gut lining, disrupting the protective barrier and exacerbating inflammation. The UC Riverside team, led by Professor Declan McCole, demonstrated that a common faulty version of the PTPN2 gene (rs1893217) increases the gut’s susceptibility to AIEC invasion. This occurs because the impaired PTPN2 function leads to an increase in “docking sites” on gut cells, making it easier for AIEC to attach and infiltrate.

Importantly, the research isn’t solely about identifying a problem; it also suggests a potential solution. The team found that treatment with JAK inhibitors – already used to manage IBD symptoms – could partially counteract the increased AIEC invasion caused by the faulty PTPN2 gene. This suggests that patients with this genetic predisposition might benefit particularly well from JAK inhibitor therapy.

The Forward Look

The implications of this research extend beyond simply refining existing treatment protocols. The identification of PTPN2 as a key player in gut health opens several avenues for future investigation. We can anticipate a surge in genetic screening for the PTPN2 variant in IBD patients, allowing for a more personalized approach to treatment. Furthermore, the discovery that PTPN2 supports the gut’s natural antimicrobial defenses suggests the possibility of developing novel therapies aimed at boosting PTPN2 activity or mimicking its protective effects.

Looking ahead, clinical trials will be crucial to validate these findings and determine the optimal use of JAK inhibitors – and potentially other targeted therapies – in patients with the PTPN2 risk allele. The research also raises questions about the potential role of PTPN2 in other inflammatory conditions beyond IBD, hinting at a broader impact on our understanding of immune regulation and gut health. Expect to see further research exploring the interplay between PTPN2, the gut microbiome, and the immune system in the coming years, potentially reshaping our approach to preventing and treating a range of inflammatory diseases.

References:

1. Chatterjee P, Canale V, King SJ, et al. The PTPN2 rs1893217 IBD risk allele increases susceptibility to AIEC invasion by a JAK-STAT-CEACAM6 axis. Gut Microbes. 2025;17(1):2526136. doi:10.1080/19490976.2025.2526136

2. Chatterjee P, Spalinger MR, Acevedo C, et al. Intestinal epithelial PTPN2 limits pathobiont colonization by immune-directed antimicrobial responses. Gut Microbes. 2025;17(1):2559029. doi:10.1080/19490976.2025.2559029

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.